Claims for Patent: 7,446,190

Summary for Patent: 7,446,190

Title:	Nucleic acids encoding chimeric T cell receptors
Abstract:	Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.
Inventor(s):	Michel Sadelain, Renier Brentjens, John Maher
Assignee:	Memorial Sloan Kettering Cancer Center
Application Number:	US10/448,256

Details for Patent 7,446,190

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Juno Therapeutics, Inc. A Bristol Myer-squibb Company	BREYANZI	lisocabtagene maraleucel	Injection	125714	February 05, 2021		2023-05-28